Recognized Interpretive Criteria Additional FDA-identified interpretive criteria Minimum InhibitoryConcentrations(mcg/mL) Disk Diffusion(zone diameter in mm) Pathogen S I R S I R Enterobacteralesa M100 standard is recognized […]

Recognized Interpretive Criteria Minimum Inhibitory Concentrations(mcg/mL) Disk Diffusion(zone diameter in mm) Pathogen S I R S I R Enterobacteralesa M100 standard is recognized Acinetobacter spp. M100 […]

Recognized Interpretive Criteria Exceptions to the recognized standard of CLSI M100 Minimum Inhibitory Concentrations(mcg/mL) Disk Diffusion(zone diameter in mm) Pathogen S I R S I R […]

Minimum InhibitoryConcentrations(mcg/mL) Disk Diffusion(zone diameter in mm) Pathogen S I R S I R Enterobacteralesa M100 standard is recognized Acinetobacter spp. ≤1 2 ≥4 – – […]

Recognized Interpretive Criteria Minimum InhibitoryConcentrations(mcg/mL) Disk Diffusion(zone diameter in mm) Pathogen S I R S I R Enterobacteralesa M100 standard is recognized Enterococcus spp. M100 standard […]

Safety Announcement [8-1-2013]  The U.S. Food and Drug Administration (FDA) is informing the public that acetaminophen has been associated with a risk of rare but serious skin […]

For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the […]

The quarterly submission deadlines for proposals to the Rare Disease Endpoint Advancement Pilot Program are March 31, June 30, September 30, and December 31.  Sponsors may […]

[6/14/2024] Today, FDA issued a proposed administrative order, to address a safety issue related to over-the-counter (OTC) monograph drug products containing acetaminophen. Based on a comprehensive […]